Literature DB >> 6097949

The relevance of tumour pH to the treatment of malignant disease.

J L Wike-Hooley, J Haveman, H S Reinhold.   

Abstract

The wide range of tumour pH values that have been determined in human tumours is shown in Fig. 4. It can be seen that tumour pH values may be very low, or may fall in the same range as the values found in normal tissues. This means that pH-mediated modification of therapeutic effectiveness will be patient specific, rather than a general phenomenon. That the pH of the cellular environment might influence the effectiveness of various therapeutic agents is not a new idea. The data published in this field to date concerning such effects have been discussed extensively and are summarized in Table IV. Here we can see that low pH leads to decreased cell survival following treatment with hyperthermia, radiotherapy combined with hyperthermia, radiosensitizers and various chemotherapeutic agents. Conversely, low pH affords some protection against radiation and some drugs. Most of these data were, of necessity, derived from in vitro studies. In vivo studies are in most cases not feasible due to the difficulty of isolating the effect of one selected factor. Low tumour pH is, in vivo, generally assumed to be closely interlinked with tissue hypoxia and low blood-flow levels, each of which may individually influence the experimental outcome. Moreover, most of the aforementioned in vitro studies were conducted under well-oxygenated conditions. As previously mentioned, euoxic cells can, under certain conditions, maintain a pH gradient over the cell membrane. This collapses with the onset of hypoxia, leading to intracellular acidification. Low oxygen levels have been shown to be characteristic of many tumours. Within these limitations it is thus evident that tumour pH values could have far-reaching consequences for therapy. If the in vitro findings should prove to be relevant to the clinical situation various applications are possible. Pre-selection of patients less likely to respond to certain (toxic) chemotherapeutic agents, or conversely selection of agents that are more likely to be effective in the pH range of the tumour to be treated are two examples. Alternatively, the exploitation of low tumour pH values is a possibility. Agents that form or release toxic derivatives in areas of low pH, e.g., pH-sensitive liposomes, will work selectively in such areas. Tumour selective therapy may also be possible in patients with higher tumour pH values if the tumour pH can be lowered. This has been achieved experimentally by the administration of hyperthermia at temperatures above 42 degrees C, or by the administration of glucose.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6097949     DOI: 10.1016/s0167-8140(84)80077-8

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  183 in total

1.  Response of hepatoma 9618a and normal liver to host carbogen and carbon monoxide breathing.

Authors:  S P Robinson; L M Rodrigues; J R Griffiths; M Stubbs
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

Review 2.  Applications of magnetic resonance in model systems: tumor biology and physiology.

Authors:  R J Gillies; Z M Bhujwalla; J Evelhoch; M Garwood; M Neeman; S P Robinson; C H Sotak; B Van Der Sanden
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 3.  Applications of magnetic resonance in model systems: cancer therapeutics.

Authors:  J L Evelhoch; R J Gillies; G S Karczmar; J A Koutcher; R J Maxwell; O Nalcioglu; N Raghunand; S M Ronen; B D Ross; H M Swartz
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 4.  Causes and effects of heterogeneous perfusion in tumors.

Authors:  R J Gillies; P A Schornack; T W Secomb; N Raghunand
Journal:  Neoplasia       Date:  1999-08       Impact factor: 5.715

5.  Combined intra-arterial chemotherapy followed by radiation in astrocytomas.

Authors:  K Watne; E Hannisdal; O Nome; B Hager; K Wester; M Heier; H Hirschberg
Journal:  J Neurooncol       Date:  1992-09       Impact factor: 4.130

Review 6.  Targeting lactate metabolism for cancer therapeutics.

Authors:  Joanne R Doherty; John L Cleveland
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

7.  An Inhibitor of the F1 subunit of ATP synthase (IF1) modulates the activity of angiostatin on the endothelial cell surface.

Authors:  Nick R Burwick; Miriam L Wahl; Jun Fang; Zhaoxi Zhong; Tammy L Moser; Bo Li; Roderick A Capaldi; Daniel J Kenan; Salvatore V Pizzo
Journal:  J Biol Chem       Date:  2004-11-04       Impact factor: 5.157

8.  Microfluidic Platform for the Isolation of Cancer-Cell Subpopulations Based on Single-Cell Glycolysis.

Authors:  Claudia Zielke; Ching W Pan; Adriana J Gutierrez Ramirez; Cameron Feit; Chandler Dobson; Catherine Davidson; Brody Sandel; Paul Abbyad
Journal:  Anal Chem       Date:  2020-04-30       Impact factor: 6.986

Review 9.  Environmentally responsive MRI contrast agents.

Authors:  Gemma-Louise Davies; Iris Kramberger; Jason J Davis
Journal:  Chem Commun (Camb)       Date:  2013-10-28       Impact factor: 6.222

10.  PDGF-A interactions with fibronectin reveal a critical role for heparan sulfate in directed cell migration during Xenopus gastrulation.

Authors:  Erin M Smith; Maria Mitsi; Matthew A Nugent; Karen Symes
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.